Oruka Therapeutics, Inc.
ORKA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EPS Diluted | -4.99 | -4.44 | -8.27 | -16.68 |
| % Growth | -12.4% | 46.3% | 50.4% | – |
| Operating Cash Flow | -$0 | – | -$0 | -$0 |
| Capital Expenditures | -$0 | – | -$0 | -$0 |
| Free Cash Flow | -$0 | – | -$0 | -$0 |